Cargando…

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus

We investigated whether belimumab treatment impacts on levels of autoantibodies and cytokines of interest in systemic lupus erythematosus (SLE). Longitudinally collected serum samples from 78 belimumab-treated Swedish SLE patients were analysed. Serum cytokine levels were determined using Luminex xM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parodis, Ioannis, Åkerström, Emil, Sjöwall, Christopher, Sohrabian, Azita, Jönsen, Andreas, Gomez, Alvaro, Frodlund, Martina, Zickert, Agneta, Bengtsson, Anders A, Rönnelid, Johan, Gunnarsson, Iva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278961/ https://www.ncbi.nlm.nih.gov/pubmed/32422945 http://dx.doi.org/10.3390/ijms21103463

Ejemplares similares

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus
por: Sohrabian, Azita, et al.
Publicado: (2019)

De novo lupus nephritis during treatment with belimumab
por: Parodis, Ioannis, et al.
Publicado: (2020)

Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis
por: Sjöwall, Christopher, et al.
Publicado: (2009)

Interferon (IFN)-λ is a potential mediator in lupus nephritis
por: Zickert, Agneta, et al.
Publicado: (2016)

B cell alterations during BAFF inhibition with belimumab in SLE
por: Ramsköld, Daniel, et al.
Publicado: (2018)

Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence
por: Gomez, Alvaro, et al.
Publicado: (2023)

Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2019)

Antiphospholipid Antibodies in Lupus Nephritis
por: Parodis, Ioannis, et al.
Publicado: (2016)

Effect of Belimumab on Preventing de novo Renal Lupus Flares
por: Parodis, Ioannis, et al.
Publicado: (2023)

B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab
por: Parodis, Ioannis, et al.
Publicado: (2022)

IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment
por: Zickert, Agneta, et al.
Publicado: (2015)

Sudanese and Swedish patients with systemic lupus erythematosus: immunological and clinical comparisons
por: Elbagir, Sahwa, et al.
Publicado: (2020)

Association of STAT4 Polymorphism with Severe Renal Insufficiency in Lupus Nephritis
por: Bolin, Karin, et al.
Publicado: (2013)

Urinary aberrations in systemic lupus erythematosus not always indicative of lupus nephritis: a cross-sectional cohort study
por: Karlsson, Linnea, et al.
Publicado: (2023)

Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis
por: Parodis, Ioannis, et al.
Publicado: (2019)

ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding HLA‐DRB1 Genotype Associations and Immunological and Clinical Manifestations
por: Diaz‐Gallo, Lina‐Marcela, et al.
Publicado: (2021)

Clinical Heterogeneity, Unmet Needs and Long-Term Outcomes in Patients with Systemic Lupus Erythematosus
por: Sjöwall, Christopher, et al.
Publicado: (2022)

Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up
por: Gerhardsson, Jakob, et al.
Publicado: (2015)

Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy
por: Parodis, Ioannis, et al.
Publicado: (2015)

Sex differences in clinical presentation of systemic lupus erythematosus
por: Ramírez Sepúlveda, Jorge I., et al.
Publicado: (2019)

IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE)
por: Oke, Vilija, et al.
Publicado: (2017)

B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice
por: Parodis, Ioannis, et al.
Publicado: (2020)

B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools
por: Parodis, Ioannis, et al.
Publicado: (2022)

Use of Antimalarial Agents Is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus
por: Gomez, Alvaro, et al.
Publicado: (2020)

Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis
por: Leonard, Dag, et al.
Publicado: (2018)

Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus
por: Jönsen, Andreas, et al.
Publicado: (2011)

Low-density granulocytes are related to shorter pregnancy duration but not to interferon alpha protein blood levels in systemic lupus erythematosus
por: Torell, Agnes, et al.
Publicado: (2023)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

Contributions of de novo variants to systemic lupus erythematosus
por: Almlöf, Jonas Carlsson, et al.
Publicado: (2020)

Comment on: Sudanese and Swedish patients with systemic lupus erythematosus, immunological and clinical comparisons: reply
por: Elbagir, Sahwa, et al.
Publicado: (2020)

High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus
por: Reid, Sarah, et al.
Publicado: (2020)

NET Formation in Systemic Lupus Erythematosus: Changes during the COVID-19 Pandemic
por: Knopf, Jasmin, et al.
Publicado: (2022)

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)

Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations
por: Mobarrez, Fariborz, et al.
Publicado: (2016)

Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus
por: Gomez, Alvaro, et al.
Publicado: (2020)

Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectives
por: Idborg, Helena, et al.
Publicado: (2019)

TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus
por: Idborg, Helena, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m2h31mpl13neln4jd75qbrpj94